Intravenous infusion of tocilizumab-bavi, first dose, for hospitalized adult patients

This code represents intravenous administration of tocilizumab-bavi (Tofidence), a biosimilar to reference tocilizumab (Actemra), an IL-6 receptor antagonist, administered to hospitalized adult patients. It is specifically indicated for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or ECMO, as well as for cytokine release syndrome (CRS). The "-bavi" suffix designates this as a distinct biosimilar product and must not be coded interchangeably with the reference biologic or other tocilizumab biosimilars.

Apply this code when tocilizumab-bavi is administered via IV infusion in the inpatient hospital setting to adults meeting clinical criteria for severe COVID-19 or CRS. Supporting documentation should include the specific biosimilar product name (tocilizumab-bavi/Tofidence), route of administration, indication, and that the patient is hospitalized. This code does not apply to outpatient or subcutaneous administration scenarios.

• Biosimilar specificity matters: Do not substitute this code for reference tocilizumab (J3262) or other tocilizumab biosimilars (e.g., tocilizumab-aazg); payers may audit for product-specific accuracy based on the NDC reported on the claim.
• NDC reporting: Many payers, including Medicare, require the 11-digit NDC of the actual product dispensed to be reported alongside this HCPCS code to confirm biosimilar identity and support reimbursement.
• Incomplete descriptor awareness: The published descriptor for this code is truncated ("for hospitalized adult patients with..."); coders should reference the full LCD/coverage policy to confirm covered indications (COVID-19, CRS) and ensure the clinical documentation aligns with payer-specific criteria.